MitoCareX Bio reports in vitro data of MITOLINE-powered small molecules

N2OFF (NITO) recently announced that MitoCareX Bio has shown preliminary in vitro data demonstrating inhibition of pro-inflammatory responses in human immune cells using its proprietary discovery platform. The company said, “Using MITOLINE-derived models, MitoCareX has assembled a focused library of small-molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing MitoCareX Bio with an initial line of evidence that mitochondrial carrier modulation can deliver anti-inflammatory benefit in human-relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome.”